新型コロナウイルス感染症に対する当社の対応について

This document outlines the measures taken by the company in response to the COVID-19 pandemic. A task force was established in March 2020 to promote infection prevention and ensure business continuity. The company is committed to maintaining a stable supply of pharmaceuticals and medical devices while continuing research and development of new drugs. To ensure the safety of employees, remote work and telecommuting are encouraged, and strict infection prevention measures are implemented. This includes daily temperature checks and workplace vaccination programs for employees and their families. The company prioritizes the health and safety of its workforce and the community.